Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?

Key Points Axsome Therapeutics' revenue is growing at a good clip. The company has a deep pipeline as well. The biotech could match Wall Street's price target over the next 12 months. 10 stocks we like better than Axsome Therapeutics › Axsome Therapeutics (NASDAQ: AXSM) has been a great stock to own over the past five years. The company's shares have climbed by about 660%. However, Wall Street remains excited about the company's prospects. Axsome Therapeutics' average price target (according to Yahoo! Finance) is $285.42, implying a 35% upside from its current level. Could the stock really gain that much over the next 12 months? Image source: The Motley Fool. Missed Nvidia in 2009? This Rare Signal Is Flashing Again.